老年人患有严重的,耐治疗的抑郁症
1Department of Psychiatry and Behavioral Sciences, UW AIMS Center, USA.
JAMA
|September 6, 2012
概括
在老年人中有效的抑郁症管理包括查,治疗启动和监测. 协作护理模式显著改善了晚年抑郁症的结果.
科学领域:
- 老年病的医生 老年病的医生
- 精神病学是一个精神病学.
- 公共卫生 公共卫生
背景情况:
- 晚年抑郁症是老年人中普遍存在的,使人衰弱和昂贵的疾病.
- 早期检测和有效干预对于管理这种人口中的抑郁症至关重要.
研究的目的:
- 总结了老年患者抑郁症检测和治疗的有效策略.
- 突出管理晚年抑郁症的系统方法的重要性.
主要方法:
- 对检测和治疗晚年抑郁症的有效策略的审查.
- 一个69岁的女性长期患有抑郁症的案例说明.
- 强调使用标准评级表进行查,并启动基于证据的治疗.
主要成果:
- 查,开始治疗 (药物或心理治疗) 和症状监测是关键.
- 没有反应的病例可能需要精神科咨询,治疗调整或电治疗.
- 维持治疗和复发预防计划对于长期康复至关重要.
结论:
- 为了缓解,需要采用多方面的方法,包括持续的监测和适应性治疗.
- 整合初级保健和心理健康专家的协作护理计划非常有效.
- 预防复发的策略,包括改变生活方式,可以降低复发的风险.
更多相关视频
相关概念视频
Long-term Depression
27.3K
Long-term depression, or LTD, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTD is the process of synaptic weakening that occurs over time between pre and postsynaptic neuronal connections. The synaptic weakening of LTD works in opposition to synaptic strengthening by long-term potentiation (LTP) and together are the main mechanisms that underlie learning and memory.
27.3K
Long-term Depression
2.6K
Long-term depression, or LTD, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTD is the process of synaptic weakening that occurs over time between pre and postsynaptic neuronal connections. The synaptic weakening of LTD works in opposition to synaptic strengthening by long-term potentiation (LTP) and together are the main mechanisms that underlie learning and memory.
Calcium Ion Concentration Mechanism
If over...
Calcium Ion Concentration Mechanism
If over...
2.6K
Psychosis: Goals of Pharmacotherapy
713
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
713
Antidepressant Drugs: MAOIs and Other Agents
1.3K
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
1.3K
Alzheimer's Disease: Treatment
1.3K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.3K
Electroconvulsive Therapy
2.6K
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
2.6K


